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Introduction
A recent study (Reducing Deaths due to Oxidative Stress, 
REDOXS) reported harm in critically ill patients who 
received glutamine supplementation [1]. Th is is in con-
trast to a number of earlier studies reporting beneﬁ cial 
eﬀ ects or failing to demonstrate any eﬀ ect [2], [3]. 
Naturally, this ﬁ nding raises a number of questions, 
which are not answered by combining all existing studies 
into a large meta-analysis. Th is overview will discuss 
existing clinical data, including dosing and selection of 
patients. In addition, suggested mechanisms will be 
discussed from a clinical perspective. Finally, possibilities 
for future research will be outlined.
Rationale for supplementation
Th e background to the suggestion that critically ill 
patients should receive glutamine supplementation is 
that plasma glutamine concentration at intensive care 
unit (ICU) admission is an independent predictor of an 
unfavorable outcome [4], [5]. Empirically, a plasma 
concentration of 420 μmol/l has repeatedly been reported 
as a cut-oﬀ  for a low plasma glutamine concentration 
associated with a higher risk of mortality in adults [4], 
[5]. In principle, the same eﬀ ect applies in critically ill 
pediatric patients, but here the low mortality rates have 
not made it possible to demonstrate a mortality dis-
advantage, although a morbidity disadvantage has been 
reported [6]. Approximately one third of ICU admissions 
are consistently found to have a low plasma glutamine 
concentration, and this is independent from conventional 
risk-scoring [1], [4]–[6]. In a study from Stockholm, the 
mortality associated with a low ICU admission glutamine 
concentration was to a large extent due to the post-ICU 
mortality within 6 months from ICU admission [5].
In addition to the predictive value of a low plasma 
glutamine concentration at ICU admission for an 
unfavorable outcome, there seem to be a similar 
prediction also for high plasma glutamine concentrations 
at admission [5]. Th is group of patients, however, is much 
smaller, and the evidence for this prediction is mostly in 
form of case series. It has been reported that acute liver 
failure is quite often associated with high or very high 
plasma glutamine concentrations [7]. Chronic liver 
insuﬃ  ciency and acute-on-chronic liver failure are not 
accompanied by high plasma glutamine concentrations. 
In single cases, it has been observed that terminal 
patients with multiple organ failure (not necessarily 
including advanced liver failure) have very high plasma 
glutamine concentrations. One can speculate that this 
observation may relate to impaired cellular integrity in 
general.
In parallel to the association between a low plasma 
glutamine and an unfavorable outcome, there is an 
extensive literature about the essential role of glutamine 
in a number of experimental systems, including whole 
animals. Cell division demands an increase in nucleotide 
production, and glutamine is a main precursor for this 
type of synthesis. Cell culture media usually contain a 
much higher free glutamine concentration than does 
human plasma, and lowering of glutamine concentration 
in cell culture media is associated with a lower rate of cell 
division. Many cultured cells prefer glutamine over 
glucose as their main energy source, and imposing 
stressful events to the cell culture is reported to enhance 
the preference for glutamine over glucose as energy 
substrate. In tissues and whole animals, it is the rapidly 
replicating cells that seem to be particularly dependent 
on glutamine availability. Enterocytes in the gastro-
intestinal tract and immune-competent cells are reported 
to be particularly sensitive to glutamine depletion. 
Histological changes and bacterial translocation in the 
gut occur when there is glutamine shortage, and 
provision of glutamine can reverse this eﬀ ect. Similarly, 
for immune-competent cells, markers of immune 
function deteriorate during glutamine shortage, to return 
back to normal upon restoration of glutamine availability.
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Targets for supplementation
With this background, the suggestion that glutamine 
shortage should be compensated for by supplementation 
is not far-fetched and consequently a number of clinical 
studies have been performed, mainly in critically ill 
patients. Behind the suggestion to supplement there are 
two diﬀ erent philosophies: To substitute a deﬁ ciency or 
to administer a pharmacological agent (pharmaco-
nutrition). It is recommended that these two philosophies 
be separated because the target for treatment is diﬀ erent 
in the two cases. To supplement to normal levels would 
mean adding supplementation in order to reach normal 
plasma concentrations, or normal availability in tissues if 
more invasive monitoring is possible. To administer a 
pharmaconutrition agent on the other hand, would mean 
that a dose-response relation is presumed and that the 
desired response eﬀ ect can be deﬁ ned. Th is eﬀ ect may be 
in terms of plasma glutamine concentrations, but may 
also be in terms of other measureable eﬀ ects related to 
glutamine intake.
When determining the target for dosing of exogenous 
glutamine supplementation, small studies of intravenous 
supplementation restoring hypoglutaminemia back to 
normoglutaminemia are usually cited [8], [9]. Th ese data 
have also been applied to enteral administration of 
supplementation, although enteral doses only marginally 
aﬀ ect plasma concentration [10]–[12]. If the pharmaco-
nutrition philosophy is applied, higher doses are usually 
given, although the rationale for doses beyond what may 
be needed to restore a low plasma concentration is purely 
hypothetical. Finally, the eﬀ ect of treatment on glutamine 
availability is only very rarely deﬁ ned in the available 
clinical studies. At best, articles report the success of 
administering the intended dose, but sometimes not even 
that is communicated in the article.
Available data make it highly unlikely that all critically ill 
patients are depleted in glutamine, as only approxi mately 
one third of patients admitted to the ICU have a plasma 
glutamine concentration <  420  μmol/l. Further more, a 
higher risk of an unfavorable outcome indicated by a high 
APACHE II score or a high sequential organ failure 
assessment (SOFA) score is not statistically associated 
with glutamine depletion. In contrast, gluta mine depletion 
at admission is not associated with risk scoring [4], [5]. 
However, the risk for a given patient may be increased if a 
low admission glutamine concentration is present 
(Figure  1). As pointed out by Rodas et al. this additional 
risk may be most pronounced for the group of patients 
with a moderate mortality risk [5]. If patient recruitment 
in a study focuses on patients with high mortality risk or 
low mortality risk, the additional risk associated with 
concomitant glutamine depletion will be less pronounced.
If exogenous glutamine supplementation aims to 
compensate for an additional risk imposed on patients 
with glutamine depletion, the target group should be 
critically ill patients with a moderate mortality risk, with 
low admission plasma glutamine concentration, who are 
in need of nutrition support for, for example, not less 
than 5 days. Th e more a study population deviates from 
this target group in which a beneﬁ cial eﬀ ect can be 
hypothesized, the less likely it will be that the study will 
show an eﬀ ect of exogenous glutamine supplementation 
attributable to glutamine supplementation.
If, on the other hand, the hypothesis is that a pharma-
cological provision of glutamine may be beneﬁ cial, the 
target group should be patients with a high mortality risk 
with a pathology likely to respond to eﬀ ects associated 
with providing a surplus of glutamine. To just combine 
all available studies of glutamine supple men tation in 
critically ill patients in a meta-analysis will not contribute 
to answering the question whether exogenous glutamine 
supplementation may be beneﬁ cial or may cause harm. It 
should be recognized that diﬀ erent studies are based on 
very diﬀ erent assumptions of the involved mechanisms.
Additional information on glutamine status in the 
individual patient, in addition to the plasma concen-
tration, can be obtained from studies about glutamine 
turnover. Available techniques use isotopically-labeled 
Figure 1. Simulation of the additional mortality prediction 
from an out of range plasma glutamine concentration at ICU 
admittance. The solid line is the APACHE II predicted mortality rate if 
plasma glutamine concentration is in the range 400–930 μmol/l; the 
dotted line represents the predicted mortality rate when admittance 
plasma glutamine concentration is outside that range. The simulation 
suggests a 50 % mortality risk at APACHE 20 for admittance plasma 
glutamine concentrations out of range in contrast to a 50 % mortality 
risk at APACHE 30 for the range 400–930 μmol/h. Reproduced from 
[5] with permission.
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glutamine to estimate the endogenous rate of appearance 
of glutamine. A limited number of studies have been 
published employing this type of technique. Available 
data show that the endogenous production of glutamine 
is in the region of 50–80  g/day in adults [13]–[16]. 
Furthermore, in healthy individuals the endogenous rate 
of appearance is higher in the fed state as compared to 
the postabsorptive state [13], [14], reﬂ ecting that intake 
of amino acids other than glutamine stimulates glutamine 
synthesis de novo mainly in skeletal muscle. Th e possible 
relationship between plasma glutamine concentration, 
endogenous rate of appearance for glutamine, and 
outcome in critical illness has so far not been deﬁ ned. In 
healthy individuals, as well as in critically ill patients, it 
has been demonstrated that exogenous glutamine supple-
mentation does not decrease the endogenous rate of 
appearance, which suggest that there is not a negative 
feed-back mechanism to decrease de novo glutamine 
synthesis when concentration is high [15], [17]. Th e 
absence of such a negative feed-back may be related to 
the fact that glutamine is an inter-organ transporter of 
nitrogen from the periphery to the liver. Th e alternative, 
free ammonia, is potentially neurotoxic, which glutamine 
is not. Th erefore, it is most likely metabolically sound to 
synthesize glutamine for this transportation and, in the 
liver, a surplus of nitrogen will be converted into urea to 
be eliminated in the urine. Th ese pathways may be 
compromised in critically ill patients with failure of these 
organs. Studies of glutamine turnover and elimination in 
critically ill patients with compromised liver and/or 
kidney function are, however, not available. To better 
deﬁ ne the possible role of exogenous glutamine supple-
mentation, more information from studies of glutamine 
kinetics and turnover are, therefore, needed.
Which patients are suitable for glutamine 
supplementation?
Th e initial studies of glutamine supplementation were 
small and involved patients who were receiving 
parenteral nutrition [18], [19]. Results were encouraging 
in terms of outcome beneﬁ ts, and although the generali-
zability of these studies was limited, meta-analyses 
including these studies indicated mortality beneﬁ ts and 
guidelines recommended intravenous supplementation 
of glutamine when parenteral nutrition was given to 
critically ill patients [20], [21]. When glutamine was given 
enterally, the results were much less conclusive, and 
meta-analyses of these results were not able to 
demonstrate beneﬁ cial eﬀ ects; consequently guidelines 
did not recommend enteral glutamine supplementation 
[20], [22]. Part of this documentation refers to trials that 
used so-called immune-nutrition, meaning that a number 
of agents with potential eﬀ ect on immune function were 
combined in the supplementation. It goes without saying 
that the results from such trials do not allow discri-
mination of the possible contributions for the individual 
ingredients in the mixtures given. Nevertheless, when 
given to critically ill patients receiving enteral nutrition, 
generally beneﬁ cial eﬀ ects have not been demonstrated 
when glutamine has been the sole supplement or part of 
a supplemented mixture [2], [3].
It is unfortunate when reviewing the literature that 
selection of patients, target for dosing, and eﬀ ect of 
treatment are often not very well motivated. Critically ill 
patients included in studies of exogenous glutamine 
supplementation are usually patients admitted to the 
ICU, sometimes conﬁ ned to only those receiving 
mechanical ventilation. Often a dichotomization is made 
related to the route of nutrition administration. Th ere is 
some empiric evidence for such a discrimination [23], 
[24], but the possible underlying mechanisms are 
obscure. Risk-scoring of patients at admission or 
sequentially during the ICU stay does not usually include 
any estimate of gut function. It is again empiric evidence 
that successful enteral feeding, indicative of a functional 
intestinal tract, is associated with a more favorable 
outcome, also in patients with comparable risk-scoring 
(only reﬂ ecting other organ systems) [25]. Hence, when 
evaluating the literature it is important to consider that 
the scales in the risk-scoring instruments are not linear 
and that the scores for selected subgroups of patients 
may not directly correspond to the prediction for 
unselected patient populations for whom the scoring 
systems were validated.
In this context, there is also reason to comment upon 
the length of treatment period. In general there is a 
marked diﬀ erence between the mean and the median 
lengths of stay in the ICU. Th is diﬀ erence reﬂ ects that the 
vast majority of patients are short-stayers, less than 4–
5 days, while a minority of patients stay for a long time in 
the ICU. Nevertheless, this small group of long-stayers 
consumes the majority of ICU days in a given unit. Th e 
variability in length of ICU stay within the patient 
population constitutes a problem when inclusion and 
exclusion criteria are to be deﬁ ned. Is it feasible that 
exogenous supplementation to a critically ill patient for 
2  days will make a diﬀ erence?; 3  days?; 5  days?; 7  days? 
On the other hand, it is often very diﬃ  cult to foresee the 
length of stay for the individual patient at ICU admission. 
It may, therefore, be reasonable to have a predeﬁ ned 
subgroup analysis of those patients who are given 
treatment for a period of time that is found suﬃ  cient for 
an eﬀ ect to be demonstrated.
Comments on recent studies with glutamine 
supplementation
With this background, it is quite clear that studies 
including patients with a high mortality risk, who are 
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poorly fed and supplied with pharmacological doses of 
glutamine are not very likely to produce results on how 
glutamine supplementation may be beneﬁ cial for 
critically ill patients. Indeed, this strategy turned out to 
be harmful, possibly attributable to the pharmacological 
doses of glutamine used [1]. Because glutamine 
supplementation given to the right patients in the right 
doses may be helpful, this result imposes the risk of 
‘killing’ the glutamine supplementation concept. To just 
look upon the critically ill patient as a ‘black box’, and to 
pour in pharmacological doses of glutamine without 
proper nutritional support and without knowledge of 
whether or not glutamine deﬁ ciency is present is 
obviously not a very good idea [26].
A neutral or non-conclusive eﬀ ect, which was the 
result of the Scottish glutamine study, would have been 
the logical result also in the REDOXS study; therefore, a 
number of important diﬀ erences between these studies 
should be highlighted. Th e Scottish SIGNET study 
included well-fed patients with a pragmatic protocol [27]. 
Th e study has been criticized for the relatively low dose 
of glutamine given, for not communicating how much of 
the intended dose the patients were actually given, and 
for the limited time period of treatment. Th e REDOXS 
study, on the other hand, was not neutral in terms of 
outcome, rather it demonstrated harm [1]. It is the ﬁ rst 
study to demonstrate harm related to provision of 
exogenous glutamine in critically ill patients. Earlier a 
report of possible harm was published in a case series of 
hematological patients with insuﬃ  cient comparability 
between patients who received extra glutamine and those 
who did not [28].
A closer look at the comparability of patients in the 
REDOXS study, also reveals a diﬀ erence between the 
patient groups that may oﬀ er an alternative explanation 
for the result of harm. Th e inclusion criterion was 
patients with ≥2 organ failures according to SOFA 
scoring, and the group given glutamine had a similar 
mean SOFA to the group not given glutamine; so far so 
good. However, if the two groups are compared in 
patients with >  2 organ failures, suddenly there is a 
statistically signiﬁ cant diﬀ erence between them (Figure 2). 
To disregard this ﬁ nding, the risk prediction by SOFA 
scoring must be assumed to be linear, but there is actually 
no evidence for such a linearity. On the contrary, there is 
evidence that mortality rate increases logarithmically 
with the number of organ failures [29]. Actually the level 
of statistical signiﬁ cance attributable to the skewed 
distribution of patients with >  2 organ failures is larger 
than the level of signiﬁ cance for the harm of pharma-
cological doses of glutamine. Th is is not a scientiﬁ c 
comparison, but the investigators of the REDOXS study 
could perform a multiple stepwise regression analysis to 
address this possible bias in patient selection.
If the increased mortality in the glutamine group of the 
REDOXS study can be associated with a diﬀ erence 
between the two groups other than the glutamine supply, 
we are suddenly in quite a diﬀ erent position. Th e 
expected non-conclusive result of the study, according to 
the chosen study population, would then no longer 
disqualify studies with protocols aimed at evaluating 
supplementation of an actual glutamine deﬁ ciency. If on 
the other hand, no other diﬀ erence than the supply of 
50  g glutamine daily can be found between the two 
groups in REDOXS, the mechanism behind the increased 
mortality must be looked for. Could short-term use of a 
bodily substance lead to intoxication? At this time-point, 
we do not know whether the patients that died in the 
REDOXS study did so with high glutamine concen-
trations. In the small subgroup of patients in REDOXS in 
which plasma glutamine concentrations were recorded, 
no information over outcome was communicated. Th e 
endogenous production of glutamine is some 50–80 g/24 h; 
will an exogenous provision of similar magnitude cause 
toxicity? Th is eﬀ ect has been reported in patients with 
liver encephalopathy, but in that situation the eﬀ ect is not 
speciﬁ c for glutamine but is reported for amino acids or 
proteins in general when given at high doses [30].
Suggestions for future research
It is obvious that more studies are needed, but it may not 
currently be possible to randomize patients to be given 
extra glutamine. At least, it cannot be considered ethical 
to give glutamine supplementation without monitoring 
plasma concentrations. However, quite large doses can be 
given enterally with only marginal eﬀ ect on plasma 
concentration. Still toxic? Obviously more observational 
studies are needed and in addition the toxicity of 
glutamine must be characterized. Is the toxicity related to 
plasma concentration?
In general, provision of glutamine by the enteral route 
only marginally inﬂ uences plasma concentration, 
Figure 2. Calculations of the likelihood of occurrence of three or 
more organ failures and of 30-day mortality rate in the REDOXS 
study related to whether randomized to glutamine (GLN) 




p  = 0.046
28-day mortality
Gln  group            n = 611




p  = 0.015
3 or more organ failures 
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whereas intravenous provision immediately leads to an 
increased plasma concentration [8]. Moreover, with a 
high rate of intravenous glutamine infusion, a steady state 
will be reached [8], [9]. Th e suggested relationship 
between a high plasma glutamine concentration at 
admission and an unfavorable outcome is based on a very 
limited number of observations, and needs to be further 
explored by observational studies. Th e connection 
between a high plasma glutamine level and acute 
fulminant hepatic insuﬃ  ciency is well known [7], but 
whether a relation between glutamine level and outcome 
in this speciﬁ c group exists is not known [30]. In chronic 
liver disease and in acute-on-chronic liver failure, high 
plasma glutamine concentrations are not observed. Th e 
manufacturer of glutamine containing dipeptides for 
intravenous use does not recommend supplementation 
to patients with liver and/or kidney insuﬃ  ciency. Th is 
recommendation is mainly based on the very limited 
documentation for this patient group, rather than actual 
data about glutamine toxicity in liver failure or kidney 
failure. Th e relationship between kidney failure and 
mortality in REDOXS is more diﬃ  cult to interpret [1]. As 
kidney failure is most often the third organ failure, 
increased mortality is seen with kidney failure in critical 
illness. Again we come back to the possibility of a skewed 
distribution between the randomized groups in that 
particular study.
Can clinical use of glutamine supplementation be 
recommended today after REDOXS? Clearly not to 
critically ill patients with two (or three) organ failures in 
the acute phase, but what about other situations? It is 
speculated that the route of glutamine administration, 
enteral or parenteral, should make a diﬀ erence. Th e 
handling of glutamine is clearly diﬀ erent with diﬀ erent 
routes of administration as reﬂ ected by the eﬀ ect on 
plasma concentration [8], [12], but is possible toxicity 
related to route of administration? It can also be 
speculated that it is the pharmacological dose of 
glutamine that is harmful. Are moderate doses safe? 
Th ese doses were used in the Scottish SIGNET study as 
well as in the Scandinavian glutamine study [27], [31]. Is 
glutamine combined with parenteral nutrition safe, while 
combination with enteral nutrition is harmful? Th is has 
recently been argued in meta-analyses in which published 
studies are divided according to how patients were fed 
[2], but is there a mechanistic rational for such a 
suggestion?
Conclusions
Th e result of the REDOXS study raises concern about 
whether or not large doses of glutamine can cause harm 
in critically ill patients. A number of peculiarities in the 
protocol of the study and in the patient selection should 
be clariﬁ ed. Th is clariﬁ cation can be done by the 
REDOXS investigators and by observational studies of 
critically ill patients. In addition, more research is needed 
to characterize the relation between endogenous 
production of glutamine and exogenous supplementation 
of glutamine in critically ill patients. Finally, glutamine 
substitution to normalize plasma glutamine 
concentrations in critically ill patients should be 
evaluated in well-conducted randomized controlled 
trials. Meanwhile, it is recommended that use of 
glutamine supplementation be restricted to situations in 
which a safety protocol is used or within clinical studies.
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